Overview
Semaglutide is a synthetic glucagon-like peptide-1 (GLP-1) receptor agonist sharing 94% sequence homology with native human GLP-1. It is chemically modified to include a C18 fatty diacid side chain and specific amino acid substitutions that confer resistance to dipeptidyl peptidase-4 (DPP-4) enzymatic degradation.
Scientific investigation of Semaglutide focuses on its biochemical interactions with pancreatic beta-cells, insulin signaling pathways, and central nervous system receptors involved in appetite regulation. All discussion herein is limited strictly to in-vitro and in-vivo animal research contexts and does not imply clinical, cosmetic, or therapeutic use.
Peptide Sequence: Modified GLP-1 (7-37) backbone with acylation
Biochemical Characteristics
Semaglutide is a modified peptide containing 31 amino acids. Critical structural modifications include the substitution of Alpha-aminoisobutyric acid (Aib) at position 8 to prevent degradation and the acylation of the lysine residue at position 26 with a spacer and a C18 fatty diacid chain. This fatty acid moiety promotes non-covalent binding to plasma albumin, significantly extending the molecule's stability in experimental environments.
Biochemical analyses demonstrate that Semaglutide exhibits high affinity and selectivity for the GLP-1 receptor. Upon binding, it activates downstream signaling cascades similar to the native ligand but with a substantially prolonged half-life, making it a valuable tool for chronic exposure studies in laboratory models.
Sequence: His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys(AEEA-AEEA-γ-Glu-17-carboxyheptadecanoyl)-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly
Molecular Formula: C₁₈₇H₂₉₁N₄₅O₅₉
Molecular Weight: 4113.58 g/mol
PubChem CID: 56843331
CAS Number: 910463-68-2
Source: PubChem
Research Applications
Semaglutide is widely utilized in laboratory research to investigate glucose homeostasis, insulin secretion dynamics, and lipid metabolism. Experimental systems include diet-induced obesity (DIO) murine models, pancreatic islet cell cultures, and assays measuring gastric emptying rates.
Additional applications include the investigation of neuroprotection, where Semaglutide is studied for its potential effects on neuroinflammation and cognitive function in rodent models of neurodegeneration. Research also explores its role in reducing hepatic steatosis and modulating cardiovascular markers under controlled experimental conditions.
Pathway / Mechanistic Context
Mechanistic studies indicate that Semaglutide acts as a specific ligand for the GLP-1 receptor. Binding initiates a signaling cascade involving the activation of adenylyl cyclase and the subsequent accumulation of cyclic adenosine monophosphate (cAMP) and activation of protein kinase A (PKA).
Gene-expression analyses further demonstrate that Semaglutide can influence transcriptional networks associated with insulin gene transcription and beta-cell proliferation. In adipose tissue research, it is observed to modulate pathways related to lipolysis and energy uptake, while central studies focus on receptor activation in the hypothalamus and brainstem.
Preclinical Research Summary
Preclinical investigations of Semaglutide include extensive in-vivo studies using rodent and non-human primate models. Research endpoints typically include the assessment of body weight trajectory, glycemic control parameters (HbA1c equivalents), and pancreatic beta-cell mass preservation.
Experimental observations report a reduction in food intake, delayed gastric emptying, and improved insulin sensitivity in subject models. Comparative studies often utilize Semaglutide as a benchmark for evaluating novel incretin mimetics. These findings are presented solely as laboratory observations without implication of clinical or therapeutic outcomes.
Form & Analytical Testing
Semaglutide is supplied as a synthetic research-grade peptide. Product identity and purity are confirmed using analytical techniques such as high-performance liquid chromatography (HPLC) and mass spectrometry (MS). Batch-specific documentation is provided where applicable.
